5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia

    John D. McCoy, Flavio A. Cadegiani, Carlos Gustavo Wambier, Sabina Herrera, Sergio Vano-Galvan, Natasha Atanaskova Mesinkovska, Paulo Müller Ramos, Jerry Shapiro, Rodney Sinclair, Antonella Tosti, Andy Goren
    Image of study
    TLDR 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
    Several studies suggest that 5-alpha-reductase inhibitors (5ARIs), commonly used to treat androgenetic alopecia (male pattern baldness), may be associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. The studies found that males with androgenetic alopecia who were taking 5ARIs had a lower likelihood of experiencing COVID-19 symptoms compared to those who were not taking the medication. However, further research is needed to confirm these findings and to determine the mechanism behind this potential association.
    View this study on onlinelibrary.wiley.com →

    Cited in this study

    Related